📰 Regeneron Eylea News

Page 3 - Regeneron Eylea News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Regeneron Eylea. Real-time updates on events, politics, business and more.

Genentech's Vabysmo Well-Received Amongst Ophthalmologists, but Use Continues to Lag the Competition, According to Spherix Global Insights

March 29, 2023

/PRNewswire/ -- According to Spherix Global Insights Launch Dynamix™: Vabysmo service, to no surprise, Regenerons Eylea continues to lead the charge in both...

Regeneron Eylea Chrystal Ferguson Scott Upham Spherix Network Corporate Communications Spherix Global Insight Launch Dynamix

Source: prnewswire.com

BioBlast w/e 24 Feb 23: Abbvie in hot water over Humira® pricing, Celltrion's Yuflyma® delays explained, Merck/Moderna mRNA vaccine/ Keytruda treatment, French Court overturns Novartis/Roche €444M cartel fine, Amgen's Amjevita® savings, Genetech new biologics facility, Regeneron new aflibercept product, Amgen's Bekemv® eculizumab

February 28, 2023

The Financial Times has reported that the Dutch Pharmaceutical Accountability Foundation (PAF), a public interest group, is suing AbbVie for…

United States France General South Korea Roche Genentech Amgen Amjevita Samsung Bioepis Merck

Source: lexology.com

Apellis: Empaveli Should Win Approval - The Future Looks Bright (NASDAQ:APLS)

January 27, 2023

Apellis has successfully guided its C3 complement inhibitor Pegcetacoplan to approval in paroxysmal nocturnal hemoglobinuria. Click here to read my analysis.

Saudi Arabia United States United Kingdom Regeneron Eylea Alexion Pharmaceuticals Apellis Pharmaceuticals

Source: seekingalpha.com

Switching Patterns Among Neovascular Age-Related Macular Degeneration: Genentech's Vabysmo Rising, Regeneron's Eylea and Genentech's Off-Label Avastin Remain Strong, According to Spherix Global Insights

January 18, 2023

/PRNewswire/ -- The switch landscape represents an active segment of the market where brands have the opportunity to capture share. Spherixs RealWorld...

Coherus Bioscience Cimerli Genentech Susvimo Scott Upham Genentech Vabysmo Regeneron Eylea Chrystal Ferguson

Source: prnewswire.com

Implications of Biosimilar Availability in the United States' Ophthalmology Markets Highlighted in New Spherix Global Insights Study

January 10, 2023

/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsungs Byooviz and...

Coherus Bioscience Cimerli Viatrisa Mylan Scott Upham Regeneron Eylea Chrystal Ferguson Genentech Lucentis

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Implications of Biosimilar Availability in the United States' Ophthalmology Markets Highlighted in New Spherix Global Insights Study

January 10, 2023

/PRNewswire/ -- Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsungs Byooviz and...

Coherus Bioscience Cimerli Viatrisa Mylan Scott Upham Regeneron Eylea Chrystal Ferguson Genentech Lucentis

Source: prnewswire.com